期刊
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
卷 37, 期 9, 页码 1666-1672出版社
WILEY
DOI: 10.1111/jgh.15917
关键词
amoxicillin; dual therapy; Helicobacter pylori; meta-analysis; vonoprazan
资金
- National Natural Science Foundation of China [82000531]
- Project for Academic and Technical Leaders of Major Disciplines in Jiangxi Province [20212BCJL23065]
- Key Research and Development Program of Jiangxi Province [20212BBG73018]
- Youth Project of the Jiangxi Natural Science Foundation [20202BABL216006]
- Key Fund of the Jiangxi Education Department [GJJ190007]
This study systematically evaluated the efficacy and safety of amoxicillin-vonoprazan dual therapy for H. pylori infection. The results showed that this therapy had comparable eradication rates to other therapies and a lower rate of side effects.
Background and Aim The efficacy and safety of amoxicillin-vonoprazan (VA) dual therapy remained unclear. Methods This systematic review was conducted in accordance with the PRISMA 2009 guidelines. A systematic search of the Pubmed, Embase, and Cochrane database was conducted using the combination of Helicobacter pylori or H. pylori or Hp, amoxicillin or penicillin, and Vonoprazan or TAK-438 or Takecab or (potassium AND competitive) or potassium-competitive. The initial and secondary outcome of this meta-analysis was to evaluate the efficacy and safety of VA dual therapy. Results Three studies and 668 H. pylori infected patients were included in this meta-analysis. The crude eradication rate of VA dual therapy was 87.5% and 89.6% by ITT and PP analysis, respectively. No significant differences were observed regarding the VA dual therapy and vonoprazan-amoxicillin-clarithromycin (VAC) triple therapy according to ITT (RR = 0.99, 95% CI, 0.93-1.05, P = 0.65) and PP (RR = 0.99, 95% CI, 0.94-1.05, P = 0.82) analysis. The side effect of VA dual therapy was 19.1% (95% CI, 5.9-32.4), which was lower than that of VAC triple therapy but there was no statistical significance (RR = 0.75, 95% CI, 0.59-1.06, P = 0.12). Conclusion VA dual therapy shows acceptable efficacy, good safety and avoid unnecessary antibiotic use in the first-line treatment for H. pylori infection. However, its application in other regions need to be further explored.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据